Recombinant human CTLA4-Ig Fusion protein（Shanghai CP Guojian）

注射用重组人CTLA4－抗体融合蛋白（三生国健）

Report date: 2022/07/15 15:12:32

Base Information

Drug NameRecombinant human CTLA4-Ig Fusion protein（Shanghai CP Guojian）
Drug Alias NameCTLA4-Ig Fusion protein - Shanghai CP Guojian PharmaceuticalRecombinant human CTLA4-Ig Fusion protein - Shanghai CP Guojian PharmaceuticalLei Ning
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCluster of differentiation 86 inhibitorsCluster of differentiation 80 inhibitors
TargetsCluster of differentiation 80Cluster of differentiation 86
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A